Trung Huynh

New Capabilities

Called the ALOFT-IPF efficacy 'encouraging, but confounding'

Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.

Updated Oct 29